B.Riley Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

October 9, 2024 6:22 AM EDT Send to a Friend
B.Riley analyst Kalpit Patel reiterated a Buy rating and $36.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).The analyst commented: "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login